Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated warning claim elements (serious infections, mortality, malignancy, MACE, and thrombosis) are directly supported by the provided FDA label sections 5.1–5.5 with no contradictions identified.
Category Scores
Accurate Statements
Serious infections are a warning risk for RINVOQ/RINVOQ LQ.
Label section 5.1 Serious Infections (serious and sometimes fatal infections; opportunistic infections; avoid in active serious infection; interrupt if serious/opportunistic infection develops).
Mortality is a warning risk for RINVOQ/RINVOQ LQ.
Label section 5.2 Mortality (higher rate of all-cause mortality observed with another JAK inhibitor; consider benefits/risks).
Malignancy is a warning risk for RINVOQ/RINVOQ LQ.
Label section 5.3 Malignancy and Lymphoproliferative Disorders (malignancies including lymphomas observed; increased malignancy rates in postmarketing safety study; NMSC; periodic skin examination for at-risk patients).
Major adverse cardiovascular events (MACE) are a warning risk for RINVOQ/RINVOQ LQ.
Label section 5.4 Major Adverse Cardiovascular Events (MACE defined; higher rate observed; patients informed; discontinue after MI or stroke).
Thrombosis (including DVT, PE, and arterial thrombosis) is a warning risk for RINVOQ/RINVOQ LQ.
Label section 5.5 Thrombosis (thromboses occurred; some resulted in death; higher rates of overall thrombosis/DVT/PE in study; discontinue if symptoms occur; avoid in patients at increased risk).
Unsupported Statements
Contradictions
Important Omissions
The AI response did not specify any of the label’s specific management/mitigation instructions for these risks (e.g., TB testing prior to use; monitoring for infection/TB; discontinue guidance for MI/stroke; discontinuation and evaluation steps for suspected thrombosis).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated content is a high-level listing of warning risks that are supported by the provided label sections; no incorrect or contradictory warning claims were made. Omission of detailed label management steps could reduce practical completeness but does not directly introduce contradiction.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The AI response confirms that these risks are present but does not include key label-directed actions/monitoring details associated with the warnings.
Suggested Improvement
Include the label’s specific risk-management instructions tied to each warning section (e.g., infection/TB evaluation and interruption/resumption guidance; TB testing and monitoring; patient counseling and discontinuation criteria for MACE; discontinue/evaluate promptly steps for suspected thrombosis).